Through an exploratory proteomic approach based on typical hepatocellular adenomas (HCAs), we previously identified a diagnostic biomarker for a distinctive subtype of HCA with high risk of bleeding, already validated on a multicenter cohort. We hypothesized that the whole protein expression deregulation profile could deliver much more informative data for tumor characterization. Therefore, we pursued our analysis with the characterization of HCA proteomic profiles, evaluating their correspondence with the established genotype/phenotype classification and assessing whether they could provide added diagnosis and prognosis values.

Approach and Results

From a collection of 260 cases, we selected 52 typical cases of all different subgroups on which we built a reference HCA proteomics database. Combining laser microdissection and mass-spectrometry–based proteomic analysis, we compared the relative protein abundances between tumoral (T) and nontumoral (NT) liver tissues from each patient and we defined a specific proteomic profile of each of the HCA subgroups. Next, we built a matching algorithm comparing the proteomic profile extracted from a patient with our reference HCA database. Proteomic profiles allowed HCA classification and made diagnosis possible, even for complex cases with immunohistological or genomic analysis that did not lead to a formal conclusion. Despite a well-established pathomolecular classification, clinical practices have not substantially changed and the HCA management link to the assessment of the malignant transformation risk remains delicate for many surgeons. That is why we also identified and validated a proteomic profile that would directly evaluate malignant transformation risk regardless of HCA subtype.

Conclusions

This work proposes a proteomic-based machine learning tool, operational on fixed biopsies, that can improve diagnosis and prognosis and therefore patient management for HCAs.

Supporting Information

References

1Bi WL, Hosny A, Schabath MB, Giger ML, Birkbak NJ, Mehrtash A, et al. Artificial intelligence in cancer imaging: clinical challenges and applications. CA Cancer J Clin 2019; 69: 127-157.
10.3322/caac.21552
PubMed Web of Science® Google Scholar
2Hricak H. 2016 new horizons lecture: beyond imaging—radiology of tomorrow. Radiology 2018; 286: 764-775.
10.1148/radiol.2017171503
PubMed Web of Science® Google Scholar
3Bass BP, Engel KB, Greytak SR, Moore HM. A review of preanalytical factors affecting molecular, protein, and morphological analysis of formalin-fixed, paraffin-embedded (FFPE) tissue: how well do you know your FFPE specimen? Arch Pathol Lab Med 2014; 138: 1520-1530.
10.5858/arpa.2013-0691-RA
PubMed Web of Science® Google Scholar
4Sala M, Gonzales D, Leste-Lasserre T, Dugot-Senant N, Paradis V, Di Tommaso S, et al. ASS1 overexpression: a hallmark of sonic hedgehog hepatocellular adenomas; recommendations for clinical practice. Hepatol Commun 2020; 4: 809-824.
10.1002/hep4.1514
CAS PubMed Web of Science® Google Scholar
5Gustafsson OJR, Arentz G, Hoffmann P. Proteomic developments in the analysis of formalin-fixed tissue. Biochim Biophys Acta 2015; 1854: 559-580.
10.1016/j.bbapap.2014.10.003
CAS PubMed Web of Science® Google Scholar
6Coscia F, Doll S, Bech JM, Schweizer L, Mund A, Lengyel E, et al. A streamlined mass spectrometry-based proteomics workflow for large-scale FFPE tissue analysis. J Pathol 2020; 251: 100-112.
10.1002/path.5420
CAS PubMed Web of Science® Google Scholar
7Henriet E, Abou Hammoud A, Dupuy JW, Dartigues B, Ezzoukry Z, Dugot-Senant N, et al. Argininosuccinate synthase 1 (ASS1): a marker of unclassified hepatocellular adenoma and high bleeding risk. Hepatology 2017; 66: 2016-2028.
10.1002/hep.29336
CAS PubMed Web of Science® Google Scholar
8Ahmed M, Broeckx G, Baggerman G, Schildermans K, Pauwels P, Van Craenenbroeck AH, et al. Next-generation protein analysis in the pathology department. J Clin Pathol 2020; 73: 1-6.
10.1136/jclinpath-2019-205864
CAS PubMed Web of Science® Google Scholar
9Jin P, Lan J, Wang K, Baker MS, Huang C, Nice EC, et al. Pathology, proteomics and the pathway to personalised medicine. Expert Rev Proteomics 2018; 15: 231-243.
10.1080/14789450.2018.1425618
CAS PubMed Web of Science® Google Scholar
10Longuespée R, Casadonte R, Schwamborn K, Reuss D, Kazdal D, Kriegsmann K, et al. Proteomics in pathology. Proteomics 2018; 18:1700361.
10.1002/pmic.201700361
Web of Science® Google Scholar
11Edmondson HA, Henderson B, Benton B. Liver-cell adenomas associated with use of oral contraceptives. N Engl J Med 1976; 294: 470-472.
10.1056/NEJM197602262940904
CAS PubMed Web of Science® Google Scholar
12Nault J, Bioulac-Sage P, Zucman-Rossi J. Hepatocellular benign tumors—from molecular classification to personalized clinical care. Gastroenterology 2013; 144: 888-902.
10.1053/j.gastro.2013.02.032
CAS PubMed Web of Science® Google Scholar
13van Aalten SM, de Man RA, IJzermans JNM, Terkivatan T. Systematic review of haemorrhage and rupture of hepatocellular adenomas. Br J Surg 2012; 99: 911-916.
10.1002/bjs.8762
PubMed Web of Science® Google Scholar
14Stoot JHMB, Coelen RJS, De Jong MC, Dejong CHC. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB 2010; 12: 509-522.
10.1111/j.1477-2574.2010.00222.x
PubMed Web of Science® Google Scholar
15Thomeer MG, Broker M, Verheij J, Doukas M, Terkivatan T, Bijdevaate D, et al. Hepatocellular adenoma: when and how to treat? Update of current evidence. Ther Adv Gastroenterol 2016; 9: 898-912.
10.1177/1756283X16663882
CAS PubMed Web of Science® Google Scholar
16Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 2015; 149: 1226-1239.e4.
10.1053/j.gastro.2015.05.061
CAS PubMed Web of Science® Google Scholar
17Nault JC, Couchy G, Balabaud C, Morcrette G, Caruso S, Blanc JF, et al. Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation. Gastroenterology 2017; 152: 880-894.e6.
10.1053/j.gastro.2016.11.042
CAS PubMed Web of Science® Google Scholar
18Bioulac-Sage P, Rebouissou S, Thomas C, Blanc JF, Saric J, Sa Cunha A, et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 2007; 46: 740-748.
10.1002/hep.21743
CAS PubMed Web of Science® Google Scholar
19Bioulac Sage P, Kakar S, Nault JC. Hepatocellular adenoma. In: WHO Classification of Tumours: Digestive System Tumours, 5th ed. Lyon, France: International Agency for Research on Cancer; 2019: 224-228.
Google Scholar
20Bayard Q, Caruso S, Couchy G, Rebouissou S, Sage PB, Balabaud C, et al. Recurrent chromosomal rearrangements of ROS1, FRK and IL6 activating JAK/STAT pathway in inflammatory hepatocellular adenomas. Gut 2020; 69: 1667-1676.
10.1136/gutjnl-2019-319790
CAS PubMed Web of Science® Google Scholar
21Rebouissou S, Amessou M, Couchy G, Poussin K, Imbeaud S, Pilati C, et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 2009; 457: 200-204.
10.1038/nature07475
CAS PubMed Web of Science® Google Scholar
22Pilati C, Zucman-Rossi J. Mutations leading to constitutive active gp130/JAK1/STAT3 pathway. Cytokine Growth Factor Rev 2015; 26: 499-506.
10.1016/j.cytogfr.2015.07.010
CAS PubMed Web of Science® Google Scholar
23Rebouissou S, Franconi A, Calderaro J, Letouzé E, Imbeaud S, Pilati C, et al. Genotype-phenotype correlation of CTNNB1 mutations reveals different ß-catenin activity associated with liver tumor progression. Hepatology 2016; 64: 2047-2061.
10.1002/hep.28638
CAS PubMed Web of Science® Google Scholar
24Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 2013; 4:2218.
10.1038/ncomms3218
CAS PubMed Web of Science® Google Scholar
25Balabaud C, Al-Rabih WR, Chen PJ, Evason K, Ferrell L, Hernandez-Prera JC, et al. Focal nodular hyperplasia and hepatocellular adenoma around the world viewed through the scope of the immunopathological classification. Int J Hepatol 2013; 2013:268625.
10.1155/2013/268625
PubMed Google Scholar
26Patitucci C, Couchy G, Bagattin A, Cañeque T, de Reyniès A, Scoazec JY, et al. Hepatocyte nuclear factor 1α suppresses steatosis-associated liver cancer by inhibiting PPARγ transcription. J Clin Invest 2017; 127: 1873-1888.
10.1172/JCI90327
PubMed Web of Science® Google Scholar
27Cadoret A, Ovejero C, Terris B, Souil E, Lévy L, Lamers WH, et al. New targets of β-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene 2002; 21: 8293-8301.
10.1038/sj.onc.1206118
CAS PubMed Web of Science® Google Scholar
28Ohta S, Misawa A, Fukaya R, Inoue S, Kanemura Y, Okano H, et al. Macrophage migration inhibitory factor (MIF) promotes cell survival and proliferation of neural stem/progenitor cells. J Cell Sci 2012; 125: 3210-3220.
10.1242/jcs.102210
CAS PubMed Web of Science® Google Scholar
29Chen JS, Li HS, Huang JQ, Zhang LJ, Chen XL, Wang Q, et al. Down-regulation of Gli-1 inhibits hepatocellular carcinoma cell migration and invasion. Mol Cell Biochem 2014; 393: 283-291.
10.1007/s11010-014-2071-x
CAS PubMed Web of Science® Google Scholar
30Di Tommaso L, Destro A, Seok JY, Balladore E, Terracciano L, Sangiovanni A, et al. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol 2009; 50: 746-754.
10.1016/j.jhep.2008.11.014
CAS PubMed Web of Science® Google Scholar
31Nault JC, Zucman-Rossi J. TERT promoter mutations in primary liver tumors. Clin Res Hepatol Gastroenterol 2016; 40: 9-14.
10.1016/j.clinre.2015.07.006
CAS PubMed Web of Science® Google Scholar
32Rizzo S, Botta F, Raimondi S, Origgi D, Fanciullo C, Morganti AG, et al. Radiomics: the facts and the challenges of image analysis. Eur Radiol Exp 2018; 2: 36.
10.1186/s41747-018-0068-z
PubMed Google Scholar
33Bioulac-Sage P, Sempoux C, Frulio N, Le Bail B, Blanc JF, Castain C, et al. Snapshot summary of diagnosis and management of hepatocellular adenoma subtypes. Clin Res Hepatol Gastroenterol 2019; 43: 12-19.
10.1016/j.clinre.2018.07.007
PubMed Web of Science® Google Scholar
34Putra J, Ferrell LD, Gouw ASH, Paradis V, Rishi A, Sempoux C, et al. Malignant transformation of liver fatty acid binding protein-deficient hepatocellular adenomas: histopathologic spectrum of a rare phenomenon. Mod Pathol 2020; 33: 665-675.
10.1038/s41379-019-0374-x
CAS PubMed Web of Science® Google Scholar
35Haider S, Pal R. Integrated analysis of transcriptomic and proteomic data. Curr Genomics 2013; 14: 91-110.
10.2174/1389202911314020003
CAS PubMed Web of Science® Google Scholar
36Sempoux C, Gouw ASH, Dunet V, Paradis V, Balabaud C, Bioulac-Sage P, et al. Predictive patterns of glutamine synthetase immunohistochemical staining in CTNNB1-mutated hepatocellular adenomas. Am J Surg Pathol 2021; 45: 477-487.
10.1097/PAS.0000000000001675
PubMed Web of Science® Google Scholar
37Lasek W, Zagożdżon R, Jakobisiak M. Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother 2014; 63: 419-435.
10.1007/s00262-014-1523-1
CAS PubMed Web of Science® Google Scholar
38Mollinedo F. Neutrophil degranulation, plasticity, and cancer metastasis. Trends Immunol 2019; 40: 228-242.
10.1016/j.it.2019.01.006
CAS PubMed Web of Science® Google Scholar
39Davenport T, Kalakota R. The potential for artificial intelligence in healthcare. Future Healthc J 2019; 6: 94-98.
10.7861/futurehosp.6-2-94
PubMed Google Scholar
40Quaglia A. Hepatocellular carcinoma: a review of diagnostic challenges for the pathologist. J Hepatocell Carcinoma 2018; 5: 99-108.
10.2147/JHC.S159808
CAS PubMed Web of Science® Google Scholar
41Tommaso LD, Spadaccini M, Donadon M, Personeni N, Elamin A, Aghemo A, et al. Role of liver biopsy in hepatocellular carcinoma. World J Gastroenterol 2019; 25: 6041-6052.
10.3748/wjg.v25.i40.6041
PubMed Web of Science® Google Scholar
42Park HJ, Choi BI, Lee ES, Park SB, Lee JB. How to differentiate borderline hepatic nodules in hepatocarcinogenesis: emphasis on imaging diagnosis. Liver Cancer 2017; 6: 189-203.
10.1159/000455949
CAS PubMed Web of Science® Google Scholar
43Faivre S, Rimassa L, Finn RS. Molecular therapies for HCC: looking outside the box. J Hepatol 2020; 72: 342-352.
10.1016/j.jhep.2019.09.010
CAS PubMed Web of Science® Google Scholar

Author names in bold designate shared co-first authorship.

Citing Literature

Volume74, Issue3

September 2021

Pages 1595-1610

Proteomic Profiling of Hepatocellular Adenomas Paves the Way to Diagnostic and Prognostic Approaches

Abstract

Background and Aims

Approach and Results

Conclusions

Supporting Information

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Proteomic Profiling of Hepatocellular Adenomas Paves the Way to Diagnostic and Prognostic Approaches

Abstract

Background and Aims

Approach and Results

Conclusions

Supporting Information

References

Citing Literature

References

Related

Information